

## Bringing in the Research Dollars! (BiRD)



**Presented by:  
The Emory+Children's Pediatric Research Center**

The monthly BiRD announcement highlights  
pediatric research funding opportunities

Contact [stacy.heilman@emory.edu](mailto:stacy.heilman@emory.edu) with questions on the funding opportunities  
highlighted below or for general research grant application advise

### **August 2011 BIRD highlights**

Grant opportunities:

- ❖ [Instrument development](#) for biomedical applications
- ❖ Host-targeted interventions for [infectious disease therapeutics](#) and research towards [advancing vaccine safety](#)
- ❖ Intervention development and interventional based research in [autism](#) and [HIV prevention and care](#) and [advancing the impact of HIV/AIDS treatment interventions](#)
- ❖ Research intense NIH Pioneer Award to fund [highly innovative research](#)
- ❖ Approaching [research in children with physical disabilities](#) through diet and exercise
- ❖ Seed grants for [innovative juvenile diabetes research](#)
- ❖ Career Development awards for [diabetes researchers](#), [junior investigators new to HIV research](#), and internal CFAR [pilots available for junior investigators and senior investigators new or returning to the field of AIDS research](#)
- ❖ Internal competition for the Burroughs Wellcome Fund [Career Award for Medical Scientists](#) and the Pew [Scholar program for research scientists](#)

Other related information and announcements:

- ❖ [Parent NIH research grant announcements](#) recently reissued for submission of investigator-initiated grant applications
- ❖ Opportunity to provide input on priorities for [future funding for neuroscience research](#) and [future funding for outcomes research](#)

### **GENERAL FEDERAL/COLLABORATIVE POTENTIAL**

**Program/Link** [Instrument Development for Biomedical Applications \(R21\)](http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-11-005.html)  
<http://grants.nih.gov/grants/guide/rfa-files/RFA-RR-11-005.html>

**Purpose** The National Center for Research Resources (NCRR), solicits innovative applications for the development of new or improved instrumentation for

biomedical research. Projects should propose tools that can be used by a wide range of biomedical or clinical researchers, and not limited to a specific organ or disease. The proposed research may involve conceptualization, design, fabrication, and/or testing of new instruments or devices, including control software. Examples of new tools and techniques that are responsive to this FOA include optical spectroscopy, mass spectrometry, electrophoresis and other separation techniques, microscopy, lasers and optics, X-ray tools, nuclear magnetic resonance spectroscopy, bioreactors, centrifugation, proteomics, genomic sequencing, functional genomics, comparative genomics, microarrays, and human sequence variation (e.g., genotyping). This list is not exhaustive, but investigators with topics outside of these areas are strongly encouraged to contact program staff to ensure that their applications are responsive.

The primary intent of this FOA is to stimulate the development of instrumentation for biomedical research that will support achievement of biomedical breakthroughs. Applications should focus on the development of more powerful and more precise technology with broad applicability to biomedical research. High-risk applications are encouraged.

|                    |   |
|--------------------|---|
| <b>Funds Avail</b> | Direct costs are limited to \$125,000 per year and maximum project period is 3 years  |
| <b>Deadline</b>    | October 11, 2011  |
| <b>Remarks</b>     | ➤ Proposals primarily focused in the areas of biomedical imaging, sensors, biomaterials, tissue engineering and rehabilitation engineering and that focus on medical informatics or bioinformatics <b><i>will be considered nonresponsive</i></b> and withdrawn without review. |

### **Program/Link Host-Targeted Interventions as Therapeutics for Infectious Diseases (R21/R33)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-11-032.html>

|                |   |
|----------------|---|
| <b>Purpose</b> | <p>The purpose of this FOA is to solicit grant applications with the goal of stimulating innovation in the discovery and development of therapeutics that target host-encoded functions required for infection, replication, spread and/or pathogenesis by one or more NIAID Category A, B, or C priority pathogens. The following applications are invited:</p> <ul style="list-style-type: none"><li>• Focused on discovery and development of a therapeutic that targets a host-encoded function required for infection by one or more NIAID Category A, B, or C priority pathogens</li><li>• Projects focused on discovery and development of such a therapeutic for a non-listed human pathogen that would also protect against a listed NIAID Category A, B, or C agent (for these projects, applicants must demonstrate the broad-spectrum capability of the proposed therapeutic)</li><li>• Responsive applications will clearly define a specific required host-</li></ul> |
|----------------|---|

pathogen interaction for development of a corresponding targeted therapeutic.

- Applications should demonstrate that the design of the potential intervention involves the careful selection of a target, and should address the development of appropriate assays, high-throughput screening for candidate drugs, and further preclinical development. Applications that focus on a therapeutic for one or more NIAID
- Category A viruses are particularly encouraged.

**Funds Avail** Support for the R21 phase cannot exceed two years and total direct costs are limited to \$275,000 over the R21 two-year period, with a maximum of \$200,000 in direct costs allowed in any single year. The R33 award phase is limited to \$300,000 in direct costs per year and cannot exceed three years. The NIAID anticipates that a maximum of fifty percent (50%) of the funded R21 phase awards will progress to the R33 award.

**Deadline** LOI: October 31, 2011  
Application: November 30, 2011

**Remarks**

- The R21/R33 is a Phased Innovation Award, the R33 being the second phase for R21 support
- NIAID intends to commit \$4 million in total costs to fund fifteen to twenty applications in FY 2012.

---

### Program/Link Research to Advance Vaccine Safety (R01)

<http://grants.nih.gov/grants/guide/pa-files/PA-08-256.html>

**Purpose** Support research that will contribute to the overall understanding of vaccine safety. This R01 research opportunity invites studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, or 4) the application of genomic/molecular technologies to improve knowledge of vaccine safety.

**Funds Avail** Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Application budgets are not limited, but need to reflect actual needs of the proposed project.

**Deadline** Standard NIH Due Dates\*

**Remarks**

- Runs in parallel with FOA of identical scientific scope under the NIH Exploratory/Developmental (R21) grant mechanism - <http://grants.nih.gov/grants/guide/pa-files/PA-08-257.html>
- NIAID, NICHD and NINR are participating organizations

---

### Program/Link Psychosocial/Behavioral Interventions and Services Research in Autism

### Spectrum Disorders (R34)

<http://grants.nih.gov/grants/guide/pa-files/PA-11-283.html>

- Purpose** To facilitate exploratory research on psychosocial/behavioral treatments and innovative services research for autism spectrum disorders, including the development of instruments to evaluate the impact of interventions on core features of autism spectrum disorders, and comorbid symptomatology. It is intended to encourage research on: 1) the development and/or pilot testing of new or adapted interventions or instruments, 2) pilot testing novel interventions in preparation for larger efficacy trials, or 3) innovative services research directions that require preliminary testing or development, as well as to facilitate the program goal of enhancing autism research through the broad availability of data and resource infrastructure to further scientific advancement and public health benefits.
- Funds Avail** Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period may not exceed 3 years.
- Deadline** Standard NIH Due Dates\*
- Remarks** ➤ Participating organizations include NICHD, NIDCD and NIMH

---

### Program/Link 2012 NIH Director's Pioneer Award Program (DP1)

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-11-004.html>

- Purpose** The NIH Director's Pioneer Award program complements NIH's traditional, investigator-initiated grant programs by supporting individual scientists of exceptional creativity who propose pioneering and possibly transforming approaches to addressing major biomedical or behavioral challenges that have the potential to produce an unusually high impact on a broad area of biomedical or behavioral research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's laboratory or elsewhere. Awardees must commit the major portion (at least 51%) of their research efforts to the Pioneer Award project.
- Funds Avail** Awards will be for up to \$500,000 in direct costs each year for five years.
- Deadline** October 7, 2011
- Remarks** ➤ The term "pioneering" is used to describe highly innovative approaches that have the potential to produce an unusually high impact on a broad area of biomedical or behavioral research, and the term "award" is used to mean a grant for conducting research, rather than a reward for past achievements.
- Biomedical and behavioral research is defined broadly in this announcement as encompassing scientific investigations in the biological, behavioral, clinical, social, physical, chemical, computational,

engineering, and mathematical sciences that have the potential to improve the public health.

- Pioneer awardees are required to commit the major portion (at least 51%) of their research effort to activities supported by the Pioneer Award program.
- NIH intends to commit approximately \$6 million for at least 7 awards in fiscal year 2012.

---

**Program/Link Health Promotion for Children With Physical Disabilities Through Physical Activity and Diet: Developing An Evidence Base (R01)**

<http://grants.nih.gov/grants/guide/pa-files/PAR-11-288.html>

- Purpose** Encourages applications that will improve our understanding of how patterns of physical activity and dietary choice affect the health and fitness of children with physical disabilities. Proposed research should account for the functional limitations of children with disabilities and their nutritional needs, as well as the physiological, psychosocial, and environmental factors that play a role in determining the health of this population. The goal of this program announcement is to better understand the special needs of children with physical disabilities, in order to develop integrated clinical and behavioral strategies to promote physical activity, reduce secondary conditions, foster healthy dietary choices, and improve health status and social participation. Of particular concern are the issues involved with promoting exercise and diet in children with disabilities from specific racial/ethnic populations and/or economically disadvantaged families.
- Funds Avail** Application budgets are not limited, but need to reflect actual needs of the proposed project. Maximum project period is 5 years.
- Deadline** Standard NIH Deadlines\*  
LOI due 30 days prior to application deadline
- Remarks**
- Companion FOA is the R21 Exploratory/Developmental Grant - <http://grants.nih.gov/grants/guide/pa-files/PAR-11-284.html>
  - The focus of this program announcement is on children with physical disabilities, but this may include comorbidities that involve cognitive and behavioral dysfunction. Thus, relevant conditions may include, but are not limited to, conditions such as cerebral palsy, muscular dystrophy, spina bifida, multiple sclerosis, spinal cord injuries, traumatic brain injury, and osteogenesis imperfecta.
  - In general, applicants should consider multidisciplinary approaches, address clear research questions, recruit an adequate sample size for the purposes of the study, and include good phenotyping and inclusion/exclusion criteria.

**Program/Link** **Juvenile Diabetes Research Foundation International (JDRF)**  
[http://www.jdrf.org/index.cfm?page\\_id=114027](http://www.jdrf.org/index.cfm?page_id=114027)

**Purpose** **Innovative Grants** - Seed funding is available for highly innovative research with potential significant impact on accelerating the mission of foundation. The innovative research should have the potential for a change in the current paradigm or conventional wisdom or to lead to a seminal discovery or to be groundbreaking. Preliminary data is not required in the proposal but the underlying premise, goal, or hypothesis must be plausible and the proposal must be focused with a well defined goal.

**Various Training & Career Development Awards** – To attract and support promising young scientists in the diabetes research field.

**Funds Avail** **Innovative Grants** - \$110,000 for 1 year

**Training/Career Development Awards** – amounts vary and last from 3-5 years depending on specific mechanism; see link for more information

**Deadline** Innovative Grants & Training/Career Development Awards – Due 9/15/11

- Remarks**
- Applicants are strongly encouraged to contact the JDRF Scientific Staff before submitting an LOI. For more detailed information about JDRF priorities and areas of research funding focus, refer to the JDRF Research Priority Areas at [http://www.jdrf.org/index.cfm?page\\_id=114356](http://www.jdrf.org/index.cfm?page_id=114356)
  - There are no citizenship requirements for these programs

**Program/Link** **Burroughs Wellcome Fund - Career Awards for Medical Scientists (CAMS)**

<http://www.bwfund.org/pages/188/Career-Awards-for-Medical-Scientists/>

**Purpose** The Career Awards for Medical Scientists (CAMS) program provides awards for physician-scientists to bridge advanced postdoctoral/fellowship training and the early years of faculty service. Proposals must be in the area of basic biomedical, disease-oriented, or translational research. Proposals in health services research or involving large-scale clinical trials are ineligible. BWF's goal with this bridge award program is to support the last year(s) of a mentored position in addition to supporting the beginning years of an independent position to facilitate the transition to a career in research.

**Funds Avail** \$700,000 over 5 years

**Deadline** **Internal Deadline: 9/5/11**

Interested applicants should submit a two-page abstract (abstract should include: your name, contact info, specific aims and hypotheses, background & significance, preliminary data where available and outline of research design & methods) and a NIH biographical sketch to Trish Haugaard [patricia.haugaard@emory.edu](mailto:patricia.haugaard@emory.edu)  
OR

Kelly Simily Shaw [ksimily@emory.edu](mailto:ksimily@emory.edu)

(If invited by Emory to submit, the agency deadline is 4pm, 10/3/11)

- Remarks**
- Eligibility requirements are fairly extensive including that the candidate must hold an MD, DDS, DVM or equivalent clinical degree and specify that candidates with tenure-track appointments as an Instructor or Assistant Professor at the time of application are not eligible.
  - To assess eligibility, click on the link below to take the eligibility quiz: <http://www.bwfund.org/pages/190/Eligibility/>

---

**Program/Link Pew Scholars Program in the Biomedical Sciences**

[http://www.pewtrusts.org/our\\_work\\_category.aspx?id=194](http://www.pewtrusts.org/our_work_category.aspx?id=194)

**Purpose** Provides funding to young investigators of outstanding promise in science relevant to the advancement of human health. The program makes grants to selected academic institutions to support the independent research of outstanding individuals who are in their first few years of their appointment at the assistant professor level.

**Funds Avail** Each Scholar will receive \$60,000 a year for 4 years.

**Deadline** **Internal Deadline:** Aug 31, 2011  
If selected by Emory to apply, agency deadline is Nov 1, 2011

**Internal Competition Guidelines:** Interested applicants must submit an abstract of their proposed projects (not to exceed 2 pages) and an NIH-style biosketch to Holly Sommers via e-mail ([hsomme2@emory.edu](mailto:hsomme2@emory.edu)) by no later than the internal deadline above for consideration. Please put *Pew Scholars Programs – Candidate Name* in the subject line of the e-mail.

- Remarks**
- Emory University may nominate only 1 candidate for this program
  - Pew Scholars may not simultaneously be supported by similar private foundation awards in excess of \$50,000 a year for the first two years of their Pew support.
  - The Program is open to individuals with a doctorate in medicine or biomedical sciences. As of November 1, 2011, candidates must hold full time appointments at the rank of assistant professor or equivalent on the faculty of the sponsoring institution. On July 1, 2012, they must not have been in such an appointment for more than three years, whether or not such appointments were on a tenure track. This time may have been spent at more than one institution. Time spent in clinical internships, residencies, or in work toward board certification does not count as part of this three-year limit.

**INTRAMURAL/SEED/PILOT**

**Program/Link** CFAR03 Developmental Grant Program

[http://www.sph.emory.edu/cms/departments\\_centers/centers/cfar/cores/dev/funding.html](http://www.sph.emory.edu/cms/departments_centers/centers/cfar/cores/dev/funding.html)

- Purpose** The CFAR03 Program is intended to help move CFAR faculty toward independent investigator status in HIV/AIDS research at NIH by funding projects to collect data, develop/refine methodologies, or develop/refine technologies that will strengthen the competitiveness of NIH applications
- Funds Avail** \$30K for 1 year
- Deadline** September 1, 2011 – deadline for initial application steps as outlined on RFA
- Remarks**
- Eligibility Criteria:
    - Junior (Assistant Professor) or Senior (Associate Professor or Professor) faculty who have no history of independent investigator-level NIH AIDS funding.
    - Senior faculty with prior independent NIH funding as long as they have not been the PI on any NIH AIDS grant within the last five years.
  - All applicants should contact Dr. Dennis Liotta (404/7276602), Dr. Ralph DiClemente (404/727-0237), or Dr. Kimberly Hagen (404/727-8855), to discuss whether your proposed project matches the mission and objectives of the Emory CFAR

**Special Interest – HIV/AIDS****Program/Link** Creative and Novel Ideas in HIV Research

<http://www.cnihr.org/requestforproposals>

**Purpose** The purpose of the Creative and Novel Ideas in Research Awards program (CNIHR) is to create a mechanism via the established Centers for AIDS Research (CFARs) to fund developmental projects to bring insight and new ideas to the HIV/AIDS field of study from early stage investigators with expertise in other disciplines. The intent of this program is to attract both international and U.S.-based young, early stage investigators from outside the field of HIV/AIDS research to help address new questions related to emerging issues of long-term survival with HIV infection and the prevention of HIV transmission.

Research topics could include any aspect of science, but may not include clinical trials of new drugs, treatments, or devices; or off-label use of a licensed drug. If an applicant is considering a study involving approved drugs and/or standard-of-care, the applicant is encouraged to contact the review administrator to determine whether the proposed project would be eligible for funding at [info@cnihr.org](mailto:info@cnihr.org).

**Funds Avail** Up to \$150,000 per year for 1-2 years

**Deadline** Concept proposals due 10/17/11  
(if selected to submit a full proposal, they are due 2/9/12)



- Remarks**
- Researchers who have had any previous grant, contract, sub-award or publication in HIV/AIDS research are not eligible.
  - Eligible investigators include junior investigators (no more than 10 years after completion of terminal degree or medical residency) and who are new to the HIV field.

---

**Program/Link** **Advancing the Impact of Effective HIV/AIDS Prevention and Treatment Interventions (R01)**  
<http://grants.nih.gov/grants/guide/pa-files/PA-11-271.html>

**Purpose** This FOA encourages research designed to increase the impact of effective HIV/AIDS-related interventions for prevention and treatment. This FOA is informed by priority areas from the National HIV/AIDS Strategy, the NIH Office of AIDS Research (OAR) Plan for HIV/AIDS Related Research, as well as the NIMH Strategic Plan ([Objective 4](#)): To strengthen the public health impact of NIMH-supported research. That is, through research, evaluation, and collaboration, to develop the capacity of NIMH to help close the gap between the development of new, research-tested interventions and their widespread use by those most in need.

The two overarching goals of this FOA are to encourage projects that will 1) improve the uptake of efficacious interventions and 2) conduct research to inform and enhance the effectiveness and efficiency of interventions, in order to maximize community impact.

**Funds Avail** Application budgets are not limited, but need to reflect actual needs of the proposed project. Maximum project period is 5 years.

**Deadline** Standard NIH Due Dates\*

- Remarks**
- Companion RFA's include
    - R03 Small Research Grant - <http://grants.nih.gov/grants/guide/pa-files/PA-11-272.html>
    - R21 Exploratory/Developmental Research Grant Award - <http://grants.nih.gov/grants/guide/pa-files/PA-11-273.html>
- R34 Clinical Trial Planning Grant Program - <http://grants.nih.gov/grants/guide/pa-files/PAR-11-274.html>

---

**Program/Link** **Discovery, Development, and Testing of Novel Interventions to Advance HIV Prevention and Care (R01)**  
<http://grants.nih.gov/grants/guide/pa-files/PA-11-275.html>

**Purpose** This FOA encourages research designed to (a) conduct tests of the efficacy of novel behavioral and/or integrated behavioral and biomedical interventions, (b) conduct basic behavioral and social science research that is needed to advance the development of innovative interventions, and (c) translate and operationalize the findings from these basic studies to develop interventions and assess their feasibility.

This FOA encourages novel, high impact research approaches that will contribute to the creation of empirically-based HIV-risk reduction approaches that could be used to pave the way for prevention, reduction of clinical impact, and cure. High impact can be achieved either by large effect size or very broad reach. To achieve these goals, this FOA outlines the need to: (1) advance combination behavioral-biomedical approaches to HIV-related interventions, (2) increase intervention potency and durability, (3) enhance targeting on high risk vulnerable populations, (4) identify new behavioral targets and intervention approaches within multiple intervention areas (e.g., to serve novel HIV prevention and treatment adherence interventions), and (5) incorporate context into intervention development and testing, thereby advancing the development and testing of interventions delivered beyond the individual level.

|                    |  |
|--------------------|--|
| <b>Funds Avail</b> | Application budgets are not limited, but need to reflect actual needs of the proposed project. Maximum project period is 5 years.  |
| <b>Deadline</b>    | Standard NIH Due Dates*  |
| <b>Remarks</b>     | <ul style="list-style-type: none"><li>➤ Division of AIDS Research at the NIMH is the participating organization</li><li>➤ Companion RFA's include<ul style="list-style-type: none"><li>○ R03 Small Research Grant - <a href="http://grants.nih.gov/grants/guide/pa-files/PA-11-276.html">http://grants.nih.gov/grants/guide/pa-files/PA-11-276.html</a></li><li>○ R21 Exploratory/Developmental Research Grant Award - <a href="http://grants.nih.gov/grants/guide/pa-files/PA-11-277.html">http://grants.nih.gov/grants/guide/pa-files/PA-11-277.html</a></li><li>○ R34 Clinical Trial Planning Grant Program - <a href="http://grants.nih.gov/grants/guide/pa-files/PAR-11-278.html">http://grants.nih.gov/grants/guide/pa-files/PAR-11-278.html</a></li></ul></li></ul> |

### ***New NIH Parent Grant Announcements***

**Program/Link** Newly Issued NIH Parent Research Grant Program Announcements  
R01 - <http://grants.nih.gov/grants/guide/pa-files/PA-11-260.html>  
R21 - <http://grants.nih.gov/grants/guide/pa-files/PA-11-261.html>  
R03 - <http://grants.nih.gov/grants/guide/pa-files/PA-11-262.html>

General information and links to all parent program announcements:  
[http://grants.nih.gov/grants/guide/parent\\_announcements.htm](http://grants.nih.gov/grants/guide/parent_announcements.htm)

**Purpose** New parent announcements are re-issued on an annual basis and are designed to enable applicants to submit investigator-initiated grant applications for specific activity codes. Below is some general information on the basic research grant program announcements and the specific links to three research project grant announcements. Feel free to contact [stacy.heilman@emory.edu](mailto:stacy.heilman@emory.edu) to discuss grant application strategies and to decide which mechanism might be most suitable for your research.

**R01: Research Project Grant (Parent R01)**

- To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his specific interest and competencies.

**R21:** NIH Exploratory/Developmental Research Grant Program (Parent R21)

- To encourage the development of new research activities in categorical program areas.
- Exploratory, novel studies that break new ground or extend previous discoveries toward new directions or applications.
- High risk high reward studies that may lead to a breakthrough in a particular area, or result in novel techniques, agents, methodologies, models or applications that will impact biomedical, behavioral, or clinical research.
- Projects should be distinct from those supported through the traditional R01 mechanism

**R03:** NIH Small Grant Program (R03)

- To provide research support specifically limited in time and amount for studies in categorical program areas.
- Small grants provide flexibility for initiating studies which are generally for preliminary short-term projects and are non-renewable.

**Funds Avail** **R01** - Application budgets are not limited, but need to reflect actual needs of the proposed project; Maximum project period of 5 years

**R21** - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. Maximum project period of 2 years

**R03** - Project period of up to two years and a budget for direct costs of up to two \$25,000 modules or \$50,000 per year.

**Deadline** Standard NIH Deadlines\*

**Remarks**

- Each Institute and Center maintains a website with areas of priority and interest. These should be reviewed carefully. Contact with an Institute or Center representative may help focus the research plan based on an understanding of the mission of the Institute or Center.
- The NIH is comprised of Institutes and Centers that support specific areas of health-related research and almost all Institutes and Centers at the NIH fund R01 grants, while only certain ones fund R21's and R03's.
- Research grant applications are assigned to an Institute or Center based on receipt and referral guidelines, and many applications are assigned to multiple Institutes and Centers as interdisciplinary and multidisciplinary research is encouraged.
- **Investigators are strongly encouraged to consult with the appropriate NIH program administrator about their proposed research project during the concept development stage of the application.**

## NOTICES/ANNOUNCEMENTS

### **Request for Information (RFI): Proposed Funding Priorities for Neuroscience Research, Resources and Tools (NIH Neuroscience Blueprint)**

<http://grants.nih.gov/grants/guide/notice-files/NOT-MH-11-016.html>

The NIH Blueprint is considering how best to invest its funds in future fiscal years. For FY2012 and FY2013, it is anticipated that limited funding will be available each year (no more than \$4 million) while FY2014 may provide greater flexibility as several NIH Blueprint projects come to an end. Keeping in mind that the NIH Blueprint is interested in ideas that are broadly relevant across diseases and participating ICs, responses are requested to the questions below:

1. Identify areas of neuroscience research that could be accelerated by the development of specific research resources or tools.
2. What are the major opportunities for, and impediments to, advancing neuroscience research?
3. What are the 2-3 highest priority tools or resources needed to capitalize on the scientific opportunities and overcome obstacles to progress in neuroscience research?
4. Describe how NIH Blueprint might best facilitate the development of these tools/resources.

All comments must be submitted electronically to: [nihblueprint@nih.gov](mailto:nihblueprint@nih.gov). Responses to this RFI will be accepted through September 9, 2011. You will receive an electronic confirmation acknowledging receipt of your response, but will not receive individualized feedback on any suggestions.

### **New Grant Opportunities in Health Services Research from the Patient-Centered Outcomes Research Institute (PCORI)**

<http://www.pcori.org/home.html>

The Patient-Centered Outcomes Research Institute (PCORI) is an independent organization created to help patients, clinicians, purchasers and policy makers make better informed health decisions. PCORI will commission research that is responsive to the values and interests of patients and will provide patients and their caregivers with reliable, evidence-based information for the health care choices they face.

PCORI is committed to transparency and a rigorous stakeholder-driven process that emphasizes patient engagement. PCORI will use a series of forums and formal public comment periods to increase awareness of its work and obtain public input and feedback prior to adoption of priorities, agendas, methodological standards, peer review processes or dissemination strategies.

#### **PCORI is currently accepting feedback on:**

- Working Definition of Patient-Centered Outcomes Research
- Initial Topics for Tier 1 Pilot Projects that will be due in Nov 2011 (LOI due date)

For more information and to record your opinions, visit the Provide Input page at <http://www.pcori.org/provideinput.html>

NIH STANDARD DUE DATES CITED ABOVE

| Mechanism(s)  | Cycle I<br>Due Date         | Cycle II<br>Due Date        | Cycle III<br>Due Date       |
|---|-----------------------------|-----------------------------|-----------------------------|
| <b>P Series</b><br>ALL – new, renewal,<br>resubmission, revision  | 25-Jan                      | 25-May                      | 25-Sept                     |
| <b>R01</b><br><b>NEW</b><br><br><i>renewal, resubmission, revision</i>  | 5-Feb<br><br><i>5-Mar</i>   | 5-Jun<br><br><i>5-Jul</i>   | 5-Oct<br><br><i>5-Nov</i>   |
| <b>T Series</b>   | 25-Jan                      | 25-May                      | 25-Sept                     |
| <b>R03, R21, R34</b><br><b>NEW</b><br><br><i>renewal, resubmission, revision</i>  | 16-Feb<br><br><i>16-Mar</i> | 16-Jun<br><br><i>16-Jul</i> | 16-Oct<br><br><i>16-Nov</i> |
| <b>K series</b><br><b>NEW</b><br><br><i>renewal, resubmission, revision</i>   | 12-Feb<br><br><i>12-Mar</i> | 12-Jun<br><br><i>12-Jul</i> | 12-Oct<br><br><i>12-Nov</i> |
| <b>All AIDS and AIDS-Related</b><br>Applications (for mechanisms<br>cited above)<br><br><i>All - new, renewal, resubmission,<br/>revision</i> | 7-May                       | 7-Sept                      | 7-Jan                       |

For the full schedule of NIH standard due dates, see  
<http://grants1.nih.gov/grants/funding/submissionschedule.htm>



**ABOUT THE BIRD:**

This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community monthly. It is compiled by the Emory-Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listserv, please e-mail [stacy.heilman@emory.edu](mailto:stacy.heilman@emory.edu) to make the request. Please also contact Stacy if you are interested in applying for any research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future funding.

